NASDAQ:CRVS

Corvus Pharmaceuticals Stock News

Healthcare > Biotechnology

Buy CRVS

*Your capital is at risk

$8.91

+0.140 (+1.60%)

At Close: Nov 17, 2025

Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript

07:16pm, Tuesday, 04'th Nov 2025

Corvus Pharmaceuticals, Inc. ( CRVS ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Leiv Lea - Chief Financial Officer Richard Miller - Co-Founder, President, CEO & Chairman

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

04:01pm, Tuesday, 04'th Nov 2025

Completed enrollment in soquelitinib atopic dermatitis Phase 1 trial extension cohort 4 (200 mg BID dose with 8-week treatment period) with data announcement anticipated in January Soquelitinib atopic

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

07:30am, Friday, 31'st Oct 2025

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

04:01pm, Tuesday, 28'th Oct 2025

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

10:00am, Friday, 17'th Oct 2025

Trial is evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1)

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

04:01pm, Thursday, 02'nd Oct 2025

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that David Moore, Executive Vice

Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts

11:31pm, Tuesday, 12'th Aug 2025

Company's soquelitinib shows promising phase 1 results in moderate-to-severe atopic dermatitis, with key phase 1 and phase 2 catalysts expected before the end of 2025. The drug's versatility targets b

Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript

03:20pm, Friday, 08'th Aug 2025

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Leiv Lea - Chief Financial Officer Richard A. Miller - Co-Founder, President

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

04:01pm, Thursday, 07'th Aug 2025

Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as earl

3 Penny Stocks Wall Street Sees With 243% Upside

09:27am, Wednesday, 11'th Jun 2025

“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

07:00am, Wednesday, 04'th Jun 2025

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demo

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by